Re: Heidi Fettke, Louise Kostos, Maria Docanto, et al. Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.015
- 15 December 2025
- journal article
- Published by Elsevier in European Urology Focus
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Prostate-Specific Antigen Levels Among Participants Receiving Annual TestingJAMA Oncology, 2025
- Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617European Urology, 2025
- Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialNature Medicine, 2025
- Prostate-Specific Antigen–Based Screening for Prostate CancerJAMA, 2018
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerCancer Discovery, 2018